Cwm LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Cwm LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,565 shares of the pharmaceutical company’s stock after acquiring an additional 190 shares during the quarter. Cwm LLC’s holdings in Vertex Pharmaceuticals were worth $2,264,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Arlington Trust Co LLC lifted its holdings in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares in the last quarter. Fortitude Family Office LLC purchased a new stake in Vertex Pharmaceuticals in the 4th quarter valued at approximately $30,000. Baystate Wealth Management LLC grew its holdings in Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the last quarter. OFI Invest Asset Management purchased a new position in Vertex Pharmaceuticals during the third quarter worth $25,000. Finally, NBC Securities Inc. acquired a new position in shares of Vertex Pharmaceuticals in the third quarter worth $34,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $397.70 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. Vertex Pharmaceuticals Incorporated has a one year low of $316.43 and a one year high of $448.40. The stock’s 50 day moving average price is $412.09 and its 200 day moving average price is $398.37. The firm has a market capitalization of $102.79 billion, a PE ratio of 28.63, a price-to-earnings-growth ratio of 1.89 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The business had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the prior year, the firm earned $3.33 earnings per share. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current fiscal year.

Insider Activity

In related news, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now owns 74,364 shares in the company, valued at $31,250,727.36. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ourania Tatsis sold 354 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock worth $5,203,249 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Maxim Group lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Wolfe Research assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, February 15th. They set an “outperform” rating and a $515.00 target price on the stock. Canaccord Genuity Group reaffirmed a “sell” rating and issued a $371.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. Finally, Truist Financial increased their price target on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.